BridgeMD
New treatment option for Febrile Neutropenia
Official title ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy
ClinicalTrials.gov ID: NCT06657183
What this study is testing
- What it's testing
- Undergoing cancer treatment comes with various risks and side effects. This clinical trial aims to reduce those risks and side effects through continuous monitoring of vital signs and blood levels.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Individuals must meet all of the following in order to be eligible to participate in the study:
- people have a diagnosis of soft tissue sarcoma, NSCLC, HNSCC, breast, pancreatic cancer, or melanoma
- For Cohort 1 (n=15), participants are eligible if starting on a new chemotherapy regimen with either: (i) high risk (\> 20%) of febrile neutropenia...
- Age \> or equal to 65 years
- Advanced disease
You likely can't join if
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Participants who cannot read or speak English
- Participants without any cellphone access
See the full eligibility criteria
- Individuals must meet all of the following in order to be eligible to participate in the study:
- people have a diagnosis of soft tissue sarcoma, NSCLC, HNSCC, breast, pancreatic cancer, or melanoma
- For Cohort 1 (n=15), participants are eligible if starting on a new chemotherapy regimen with either: (i) high risk (\> 20%) of febrile neutropenia as per NCCN MGF guidelines; or (ii) intermediate risk for febrile...
- Age \> or equal to 65 years
- Advanced disease
- Previous Chemotherapy or Radiation therapy
- Preexisting neutropenia or bone marrow involvement with tumor
- Infection
- Open wounds or surgery in last 4 weeks
- Poor performance status or poor nutritional status
- Poor renal function (cr clearance \<50)
- Total Bilirubin \>1.5 upper limit of normal
- Cardiovascular Disease
- Multiple Co-morbidities
- HIV infection
- BMI \> 2.0
- For Cohort 2 (n=15) participants are eligible if starting on immunotherapy alone, or concurrent chemo-immunotherapy.
- Participants are capable of giving informed consent
- Participants must be able to read and/or to speak English
- Participants who are 18 years of age or older
- Expected chemotherapy treatment duration of at least 12 weeks
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Participants who cannot read or speak English
- Participants without any cellphone access
The study team makes the final eligibility decision.
Where it's taking place
- Cleveland, Ohio, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Cleveland, Ohio, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.